Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness

Omalizumab is an effective therapeutic humanized murine IgE antibody in many cases of primary systemic mast cell activation disease (MCAD). The present study should enable the clinician to recognize when treatment of MCAD with omalizumab is contraindicated because of the potential risk of severe ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Molderings, G. J., Dumoulin, F. L., Homann, J., Sido, B., Textor, J., Mücke, M., Qagish, G. J., Barion, R., Raithel, M., Klingmüller, D., Schäfer, V. S., Hertfelder, H. J., Berdel, D., Tridente, G., Weinstock, L. B., Afrin, L. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419348/
https://www.ncbi.nlm.nih.gov/pubmed/32377770
http://dx.doi.org/10.1007/s00210-020-01886-2

Ejemplares similares

Ejemplares similares